SNES - צמיחת הכנסות משנה לשנה ב-12 החודשים האחרונים SenesTech, Inc.

SenesTech, Inc. is developing eco-friendly rodent protection for agricultural holdings through strategic alliances, minimizing crop spoilage. Relative revenue growth over the last four quarters compared to last year demonstrates sales dynamics, where the 21.20 metric determines this level. Robotic dosing lines ensure stable product output, facilitating the expansion of the customer base as the industry shifts toward safe biological preparations.

SenesTech, Inc. (SNES) is strengthening its market position through exclusive rights to the non-lethal drug ContraPest. The sales dynamics of this product are digitized by comparing current annual revenue with the same period of the previous cycle. A daily TTM rolling window calculation smooths gaps between quarterly reports, ensuring continuous monitoring of expansion rates. The upward trend confirms the effectiveness of government contracts. By analyzing this TTM year-over-year revenue chart, investors can assess the stability of the patent monopoly.